Announcement: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection

Last updated: 13/06/2026 04:51

0 Min Read

Phase 1b trial shows manufactured 15-strain biotherapeutic achieves similar efficacy to traditional fecal transplant in treating recurrent C. difficile infection. Both treatments demonstrated 85-90% success rates. — Photo: National Institute of Allergy and Infectious Diseases / Pexels

1 min read|40 words

Breakthrough: Manufactured 15-strain biotherapeutic achieves 85-90% success rate matching traditional fecal transplant for recurrent C. diff infections. Phase 1b trial shows standardized microbiome therapy could offer safer, scalable alternative to whole stool FMT.

Read the full article on GMJ Newsroom →

Was this article helpful?

GMJ Brief · Announcement

📰 Read the full article: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection →

Share This Article

ByProf. Giorgi Pkhakadze

Follow:

Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Announcement: Live biotherapeutic matches donor FMT in treating recurrent C. diff infection

Submit Your Paper →

NEJM Images Show Advanced Diabetic Eye Disease Progression and Treatment Response

NHS workforce crisis threatens patient safety as early career doctors report severe burnout

GLP-1 Drugs Show 30% Lower Breast Cancer Risk in Major Study

Submit Your Paper to GMJ

Company

You Might Also Like